Atsena Therapeutics

We are excited to announce Christine Kay, MD, will present safety and efficacy data for ATSN-201, our best-in-class investigational #GeneTherapy candidate to treat X-linked retinoschisis (#XLRS), at the upcoming American Academy of Ophthalmology (AAO) 2024 Annual Meeting in Chicago!   ATSN-201 is being evaluated in the LIGHTHOUSE study, a Phase I/II clinical trial in male patients with XLRS due to RS1 gene mutations. To learn more about the AAO 2024 Annual Meeting click here: https://lnkd.in/dFPgwyFg   Visual description: The graphic announces the details of the upcoming presentation at the American Academy of Ophthalmology 2024 Annual Meeting including: Presenter: Christine Nichols Kay, MD Presentation Date & Time: Friday, October 18, 2024, at 5:08 PM CDT Presentation Topic: "Interim Safety and Efficacy of ATSN-201 Dose Escalation Study in Patients with X-linked Retinoschisis(XLRS)" Session: First-time Results of Clinical Trials The background features a gradient from purple to blue, with a picture of Dr. Kay to the right. The Atsena Therapeutics logo is at the bottom right.   https://lnkd.in/ee7YGYFF

Our Director of Patient Advocacy, Kara Fick, had a great time joining Fighting Blindness Canada at View Point Toronto to hear about #InheritedRetinalDiseases and the lived experiences of individuals with vision loss. View Point is an educational series that brings the latest information about vision health and research to the community. As leaders in the field of ocular #GeneTherapy, we are passionate about advancing solutions to reverse or prevent blindness and engaging with the community.   Visual description: A collage of images highlights the VIEW POINT event hosted by Fighting Blindness Canada. It showcases different moments including Atsena’s Director of Patient Advocacy Kara Fick next to a sign that reads "VIEW POINT," a panel discussion with multiple speakers seated on stage with a backdrop displaying the Fighting Blindness Canada logo, another stage featuring two speakers having a conversation and an image of event materials on a table, including a VIEW POINT program, a bag with the Fighting Blindness Canada logo, and various branded items including a pen and magnifying glass. The Atsena Therapeutics logo is at the bottom right.

Exciting news from University of Florida startup Atsena Therapeutics! The FDA has granted Rare Pediatric Disease designation to ATSN-201 for the treatment of X-linked retinoschisis (XLRS). This prestigious designation is reserved for drugs targeting serious conditions that affect fewer than 200,000 patients in the U.S., highlighting the potential of ATSN-201. Leveraging the innovative AAV.SPR capsid, ATSN-201 aims to achieve effective gene expression in central retina photoreceptors while minimizing the risks of foveal detachment. Currently, there are no approved treatments for XLRS, which affects around 30,000 males in the U.S. and EU. This achievement marks the second Rare Pediatric Disease designation granted to Atsena this year! The ongoing LIGHTHOUSE study is evaluating ATSN-201's safety and efficacy in patients aged six and older. Kudos to Atsena for their dedication to transforming the future for those affected by inherited retinal diseases! 👏🔬✨

Atsena is proud to stand with the global community in recognizing World Retina Day, a day dedicated to raising awareness for retinal diseases and the people impacted by them. Retinal diseases, including #InheritedRetinalDiseases (IRDs), affect millions of people worldwide, often leading to vision loss or blindness. We are committed to advancing #GeneTherapy treatments that have the potential to improve sight for those living with IRDs.   Today, we honor the resilience of patients, the dedication of caregivers, and the work of researchers and advocates across the globe. Together, we can illuminate the path toward better vision for all.   Visual description:   The image features a close-up human eye. Circular design elements in blue and orange partially outline the eye. The background is a gradient of deep purple to lighter blue shades. The text on the left side of the image reads:   At the top in a small orange rectangle: "September 29 is" Below it in large white, bold letters: "WORLD RETINA DAY"   The Atsena Therapeutics logo appears in the bottom left corner.

At Atsena Therapeutics, we are driven by a shared mission: to restore and preserve vision for those affected by #InheritedRetinalDiseases. Our journey is fueled by passion, innovation and a deep commitment to making a difference in patients' lives.   In this video, you'll get an inside look at the heart of Atsena—the leaders and founders (Shannon Boye, Sanford Boye, Patrick Ritschel, Kenji Fujita) who have dedicated their careers to pioneering #GeneTherapy treatments that address unmet medical needs.    We’re excited to share our story with you and invite you to learn more about the people who are shaping the future of vision restoration.   Visual description: In this image, a woman wearing a white lab coat is speaking with a man in a medical research facility. The woman is smiling at the camera while pointing to a computer screen that is displaying a scientific image.

Atsena #CEO Patrick Ritschel will present a corporate update during Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1 at 11:30 a.m. ET. Atsena #CMO Kenji Fujita and Mr. Ritschel will also participate in one-on-one meetings.    Visual description: The image displays a blue-themed banner with the following text in bold, white font: "Atsena Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference." In the top right corner is the Atsena Therapeutics logo. The background is darker blue tones, and at the bottom, there are wave-like shapes in shades of blue. https://lnkd.in/eccqqXSz

Atsena Therapeutics, announced that the FDA has granted Orphan Drug Designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). According to the company, ATSN-201, a gene therapy product candidate, leverages AAV.SPR, Atsena’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment. Read More: https://ow.ly/xOli50Tppno

Atsena Therapeutics announced the FDA has granted Orphan Drug designation (ODD) for ATSN-201, a gene therapy candidate intended to treat X-linked retinoschisis (XLRS), just one month after receiving Rare Pediatric Disease designation (PDD). Learn more on Glance: https://lnkd.in/dZeZ45eU #GlanceNews #FDA #eyecare Mallory Bissett, MBA

We are thrilled to announce that the FDA has granted Orphan Drug Designation to Atsena Therapeutics for our best-in-class #ocular #GeneTherapy ATSN-201, targeting X-linked retinoschisis (XLRS), a rare #InheritedRetinalDisease with no approved treatments that affects approximately 30,000 males in the U.S. and EU.   This important milestone comes shortly after ATSN-201 received Rare Pediatric Disease designation from the FDA and recognizes the significant unmet need for treatment options for those affected by XLRS. It also underscores our commitment to pioneering innovative gene therapies that improve patients’ lives. https://lnkd.in/efaJfm_R   Visual description:   The image features a photograph of Patrick Ritschel, Chief Executive Officer of Atsena Therapeutics. To the right of his photo, there is a quote attributed to him:   "We are honored to receive the FDA’s Orphan Drug Designation for ATSN-201, which was also recently granted Rare Pediatric Disease designation. These designations mark a significant inflection point for the potential of this ocular gene therapy. We are confident these designations will expedite our path forward."   At the bottom of the quote, his name and title appear. In the bottom right corner is the Atsena Therapeutics logo in white, along with the company name written in capital letters. A gradient background transitions from purple at the top to blue at the bottom, featuring a pattern of small dots. There are curved lines in blue, orange, and purple encircling the photograph of Patrick Ritschel.

Our Chief Medical Officer, Kenji Fujita, MD, will speak at the Gene Therapy for Ophthalmic Disorders Summit from September 10-12 in Boston! Dr. Fujita will share insights and the latest ocular #GeneTherapy advancements on innovative treatments for #InheritedRetinalDiseases. If you’re attending, please join him on Thursday, September 12 at 9:30 a.m. ET for the “Maximizing Ophthalmic Gene Therapy Trial Success Strategies” panel discussion and again at noon ET for “Exploring XLRS Cohort Update: Dosing, Safety, and Efficacy Insights,” where he will discuss more about the ocular gene therapy ATSN-201. Visual description: On the left side, there is a picture of Atsena Therapeutics' CMO, Dr. Kenji Fujita, MD, and the background behind him is a solid purple gradient that fades to a lighter shade, providing a contrasting backdrop. On the right side, the text reads “Atsena CMO Kenji Fujita, MD to present at the "GENE THERAPY FOR OPHTHALMIC DISORDERS SUMMIT.” The bottom part of the image features abstract, curved lines in shades of blue and gray, and the Atsena Therapeutics logo is positioned in the bottom right corner, with the company's name in dark blue and the logo symbol in a blend of blue, orange, and purple.